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Abstract
Background: Adoptive cell transfer of tumor-specific T lymphocytes (T cells) is proving to be an effective strategy
for treating established tumors in cancer patients. One method of generating these cells is accomplished through
engineering bulk T cell populations to express chimeric antigen receptors (CARs), which are specific for tumor antigens.
Traditionally, these CARs are targeted against tumor antigens using single-chain antibodies (scFv). Here we describe the
use of a designed ankyrin repeat protein (DARPin) as the tumor-antigen targeting domain.
Methods: We prepared second generation anti-HER2 CARs that were targeted to the tumor antigen by either
a DARPin or scFv. The CARs were engineered into human and murine T cells. We then compared the ability
of CARs to trigger cytokine production, degranulation and cytotoxicity.
Results: The DARPin CARs displayed reduced surface expression relative to scFv CARs in murine cells but
both CARs were expressed equally well on human T cells, suggesting that there may be a processing issue
with the murine variants. In both the murine and human systems, the DARPin CARs were found to be highly
functional, triggering cytokine and cytotoxic responses that were similar to those triggered by the scFv CARs.
Conclusions: These findings demonstrate the utility of DARPins as CAR-targeting agents and open up an
avenue for the generation of CARs with novel antigen binding attributes.
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Background
Cancer immunotherapy aims to treat tumors by engaging
the patient’s immune system. One form of immunother-
apy, called adoptive cell transfer, infuses cancer patients
with a bolus of tumor-specific T lymphocytes (T cells),
and is proving to be an effective treatment for a variety of
malignancies [1–3]. In adoptive cell transfer, T cells iso-
lated from a tumor-bearing patient are grown to large
numbers ex vivo and are administered back into the pa-
tient to induce a robust anti-tumor immune response.
Tumor specificity can be achieved by either i) isolat-
ing naturally occurring tumor-specific T cells from
the patient, or ii) engineering bulk T cells from the
peripheral blood to express tumor-specific receptors
on their surface. Naturally-occurring tumor-specific T
cells are rare and expanding them from a cancer patient is
typically a laborious procedure. In contrast, it is becoming
relatively easy to engineer readily-available peripheral
T cells with tumor-specific receptors through genetic
manipulation. Techniques have been developed for
this engineering process which are clinically-viable
and multiple clinical trials have demonstrated feasibil-
ity and efficacy of genetically-engineered T cells for
the treatment of cancer [1, 3–9].
Chimeric antigen receptors (CARs), recombinant pro-
teins designed for expression on the surface of T cells,
offer one way to engineer T cells with anti-tumor func-
tionality. CARs are composed of an extracellular antigen
recognition domain linked to intracellular signaling do-
mains derived from the T cell receptor and co-receptors
(including combinations of the signaling regions of
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CD3ζ, CD28, and/or 4-1BB, for example) such that the
T cells become activated following binding of tumor
antigen by the CAR. Depending upon the nature of the
intracellular signaling domains, this activation event can
lead to cytokine production, cytotoxic attack of the
tumor, and proliferation of the T cells.
Most CARs developed to date, including those spe-
cific for the tumor associated antigens human epider-
mal growth factor receptor 2 (HER2) [4, 10] and CD19
[3, 7, 8], utilize a single-chain variable fragment (scFv),
derived from an antibody, to enable antigen recognition.
However, scFvs do not represent the sole or, necessarily,
the optimal option for antigen targeting of CARs.
Ankyrin repeats (ARs), one of the most common
protein motifs found in nature, are 33 amino acid
long sequences composed of a β-turn followed by two
anti-parallel α-helices and a loop [11, 12]. Various
numbers of these individual ARs stack together to form
ankyrin repeat proteins which function as protein binders
[11, 13]. Recognizing the potential of these natural ankyrin
repeat proteins as alternative target-binding domains,
libraries of artificial stacked ARs, called designed ankyrin
repeat proteins (DARPins) were developed to allow for the
generation of repeat protein binders against a defined
target of interest [14, 15]. Each DARPin in these libraries
typically consists of between 2 and 6 repeating units; 2–4
repeats containing both fixed (framework sites required
for correct AR folding) and variable (randomized sites
leading to a diversity of target-binding capacity within the
library) amino acid positions sandwiched between non-
variable N-terminal and C-terminal capping repeats (es-
sential for correct DARPin folding) [16, 17]. Expression of
these genetic DARPin libraries using ribosome or phage
display systems allows for the selection of DARPins with
the capacity to bind a defined target of interest as well as
refine binding affinity for that target [18].
DARPins offer a number of features which make them
attractive for use in the CAR field: 1) they are more
compact than scFvs and, thus, take up less space in the
genetic transfer vectors typically used for engineering T
cells (ex. retrovirus and lentivirus), 2) they are very
thermodynamically stable, and 3) they do not require
pairing of separate binding domains (e.g. VH and VL of
the scFv), allowing the facile linkage of multiple DAR-
Pins, with different specificities, which could be used to
create a multi-specific CAR.
We tested the utility of DARPins to target CARs
using a DARPin specific for the tumor associated
antigen HER2 [19]. As a gold standard, we employed
an scFv against HER2 [20]. Both targeting elements
were incorporated into murine and human CAR
scaffolds to rigorously test the suitability of DAR-
Pins. Our results demonstrated that targeting CARs
with DARPins is as efficacious as targeting CARs
with scFvs and supports the further investigation of
DARPin CARs.
Results and discussion
Expression of DARPin28z on murine and human
T lymphocytes
To generate a chimeric antigen receptor which uses a
DARPin for its antigen recognition domain, we exchanged
the scFv domain of a second generation CAR with specifi-
city against HER2 [20] (herein referred to as scFv28z) with
a HER2-specific DARPin [19] (herein referred to as DAR-
Pin28z) (Fig. 1a, b). We created both a murine and a hu-
man version of both CARs to allow for testing of the
DARPin antigen-binding domain in T cells from both spe-
cies. We noted that the DARPin28z CAR displayed
reduced surface expression on T cells from both C57BL/6
and BALB/c mice relative to the scFv28z CAR (Fig. 1c, d).
While we do not know the reason for the reduced surface
expression, the effect appeared to be related to the murine
system because the human DARPin28z receptors were
expressed at high levels on T cells from two different do-
nors and displayed surface expression levels equivalent to
the scFv28z CAR in the human T cells (Fig. 1c, e). To-
gether these data indicate that DARPin28z is successfully
expressed on the surface of both murine and human T
lymphocytes.
DARPin28z induces cytokine production by CAR-T cells
upon antigen binding
To test the functionality of the DARPin28z CARs, we
stimulated the engineered murine and human T cells
with recombinant HER2 or an unrelated control protein
(recombinant kinase insert domain receptor (KDR), also
known as vascular endothelial growth factor receptor 2
(VEGFR-2)) and measured the production of cytokines
using flow cytometry. Murine T lymphocytes expressing
the scFv28z CAR produced both IFN-γ and TNF-α upon
stimulation with HER2, as did the same cells expressing
the DARPin28z CAR (Fig. 2a). Both scFv28z and DAR-
Pin28z were able to trigger IFN-γ and TNF-α production
in a similar proportion of retrovirally engineered T cells
(those expressing the transduction marker Thy1.1)
(Fig. 2b). However, the level of CAR expression by retrovi-
rally transduced (Thy1.1 positive) cells varied significantly
between scFv28z and DARPin 28z CAR-T cells (Fig. 1d),
and when cytokine production data was normalized for
CAR-expression, DARPin28z was more effective at indu-
cing IFN-γ and TNF-α double-producing T cells on a per-
CAR-T cell basis (Fig. 2c). Indeed, similar results were
observed for human T cells; DARPin28z was able to trig-
ger production of both IFN-γ and TNF-α by human T
cells (Fig. 3a). In fact, in human T lymphocytes, DAR-
Pin28z proved more efficient than scFv28z at inducing
cells producing IFN-γ and TNF-α among NGFR-positive

















































































Fig. 1 (See legend on next page.)
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cells (lentivirally engineered T cells); IFN-γ+ TNF-α–:
11.7 ± 2.6 vs 17.0 ± 5.2 (p < 0.05), IFN-γ+ TNF-α+:
12.2 ± 2.2 vs 28.8 ± 7.5 (p < 0.001), IFN-γ– TNF-α+:
6.7 ± 1.2 vs 11.7 ± 3.1 (p < 0.05). Furthermore, DAR-
Pin28z was also more efficient at inducing production
of IL-2 by human CAR-T cell cultures (Fig. 3b), although
showed no enhanced capacity to induce degranulation of
HER2 stimulated CAR-T cells, as determined by CD107a
release (Fig. 3c). Since the T cell populations are comprised
of a constellation of cells with distinct functional pheno-
types, we also employed SPICE analysis to determine
whether the two CARs selectively activated a particular
subpopulation of cells, but this analysis revealed no prefer-
ential activation of a particular subpopulation by either
CAR (Fig. 3d).
Observed differences in the magnitudes of response
may be explained by variances in target binding by the
anti-HER2 DARPin vs anti-HER2 scFv. For example,
the anti-HER2 DARPin utilized here has an affinity for
HER2 of 0.070nM [21] while the scFv has an affinity
of 7.2nM [22]. In addition, the scFv used to generate
our scFv28z CAR (FRP5 [20, 22]) binds to the distal-
most extracellular loops of HER2 [23], whereas the
anti-HER2 DARPin used to generate our DARPin28z
CAR binds HER2 proximal to the cell membrane [24],
which may influence epitope availability. While these
differences negate any direct comparisons between
DARPin28z and scFv28z efficacy, the above data reveals
that the DARPin28z CAR demonstrates an equivalent
capacity to activate T cell effector functions, specifically
cytokine production, as the scFv28z CAR.
DARPin28z induces CAR-T cell cytotoxicity against
HER2-positive tumor cells
To test the capacity of our DARPin28z CAR-T cells to in-
duce cytotoxicity against HER2-positive tumor cell targets,
engineered murine and human CAR-T cells were incu-
bated with a variety of HER2-positive and HER2-negative
tumor cell lines; viability of the cell lines was measured
6 h later. HER2-positive cell lines included murine D2F2/
E2, a murine breast carcinoma engineered to express
human HER2, as well as SKBR3 and HCC1954, human
breast carcinomas which naturally overexpress HER2.
HER2-negative cell lines included D2F2, a murine breast
carcinoma (the parental line of D2F2/E2), and LOX-IMVI,
a human melanoma cell line. HER2 expression status on
tumor cells was verified via flow cytometry (Fig. 4a).
Murine DARPin28z CAR-T cells showed minimal killing
of HER2-negative tumor cells (Fig. 4b) but were able to
kill HER2-positive tumor cells at effector(E):target(T)
ratios of as low as 0.6 T cells per tumor cell (D2F2/E2 and
HCC1954, Fig. 4c, e) and 1 T cell per tumor cell (SKBR3,
Fig. 4d). Levels of tumor cell killing were similar between
scFv28z and DARPin28z CAR-T cells, with the exception
of SKBR3 tumor cells, against which DARPin28z CAR-T
cells showed increased cytotoxicity compared to scFv28z
(Fig. 4d). Human DARPin28z CAR-T cells behaved simi-
larly; HER2-negative tumor cells showed minimal cell
death after incubation with CAR-T cells at all E:T ratios
tested (Fig. 4f, j) while HER2-positive tumor cells showed
evidence of cytotoxicity starting at E:T ratios of 0.1 CAR-
T cells per tumor cell (D2F2/E2, Fig. 4g) and 2 CAR-T
cells per tumor cell (SKBR3, HCC1954, Fig. 4h, i). Human
DARPin28z CAR-T cells were equally as cytotoxic as their
scFv28z counterparts against SKBR3 targets (Fig. 4f), but
showed superior induction of cytotoxicity against D2F2/
E2 targets at all E:T ratios tested (Fig. 4g) and HCC1954
targets at a 2:1 E:T ratio (Fig. 4i). As such, we can con-
clude that the DARPin28z CAR is capable of activating T
cells to induce cytotoxicity against a HER2-positive tumor
target while sparing target-negative cells. These data, simi-
lar to the results generated following stimulation with re-
combinant HER-2, confirm that the DARPin28z receptors
demonstrate biological activity that is similar to the
scFv28z receptor.
Conclusions
These experiments position DARPin-targeted CARs as a
suitable alternative to their scFv-targeted counterparts
and strongly support the further investigation of DAR-
Pins for use targeting CARs; by all measures investi-
gated, DARPin28z performed similarly to scFv28z as a
(See figure on previous page.)
Fig. 1 Expression of scFv28z and DARPin28z on the surface of murine and human T lymphocytes. a Schematic representation of CAR structures.
Each construct was composed of an antigen recognition domain (either scFv or DARPin), specific for HER2, fused to a myc tag, CD8α hinge,
CD28 transmembrane and signaling domains, and the signaling portion of CD3ζ. Identical constructs were generated for expression in murine or
human T cells, using species specific sequences for CAR components. b Schematic showing orientation of CAR structures in relation to the T cell
surface. Ribbon diagrams for the scFv and DARPin domains illustrate differences in tertiary structure and size. c-e CAR expression on the surface
of murine (BALB/c or C57BL/6) or human T cells was analyzed by flow cytometry. All plots show virally transduced CD8+ lymphocytes
(CAR-expressing viruses also expressed transduction markers; Thy1.1 for murine constructs and NGFR for human constructs). CAR negative
cells were used as controls; T cells were transduced with constructs expressing transduction markers in the absence of a CAR. CAR expression
was measured by staining with an α-myc tag antibody, or a HER2Fc fusion protein, followed by a secondary detection antibody. c. Representative plots
are shown. d-e Level of CAR expression by transduced cells; calculated for murine ((d) % CAR+/% Thy1.1+) and human ((e) % CAR+/NGFR+) CAR-T cell
cultures. Data representative of multiple experiments ((d) murine: CAR –’ve n = 3, scFv28z n = 6, DARPin28z n = 6) ((e) human: two donors, n = 3 each
for CAR –’ve, scFv28z, DARPin28z). Error bars = standard deviation (SD). * = p < 0.05 ** = p < 0.005 *** = p < 0.001
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mechanism for targeting T cells against a HER2-positive
target.
In our opinion, DARPins offer a number of attract-
ive features as an antigen-targeting domain. First,
DARPins are smaller than scFvs; our anti-HER2 scFv
is 739 bp [20] compared to 408 bp for the anti-HER2
DARPin [19]. Since lentivirus titers are often inversely
correlated with the size of the lentiviral insert [25, 26], the
ability to conserve coding sequence in the lentivirus
insert is a desirable feature afforded by using DAR-
Pins. Second, it has been argued that DARPins are
poorly immunogenic [16, 17], a useful property for
the safety and longevity of DARPin-based CAR-T cell
therapies. Finally, ARs are amenable to stacking; the
number of ARs stacked consecutively in a single pro-
tein ranges from one to 33 [11]. As such, we postu-
late that several DARPin molecules, each with unique
antigen-binding properties, could be stacked consecu-




Parental D2F2 and human HER2 expressing D2F2/E2
murine mammary tumor cell lines (provided by Dr.
Wei-Zen Wei, Barbara Ann Karmanos Cancer Insti-
tute, Detroit, MI) were cultured in hi-glucose DMEM
supplemented with 5 % FBS (Gibco; Life Technolo-
gies, Grand Island, NY), 5 % cosmic calf serum
(Fisher Scientific, Waltham, MA), 2.4 mM L-glutam-
ine (BioShop Canada Inc., Burlington, ON), 0.12 mM
non-essential amino acids (Gibco), 120U/mL penicillin
(Gibco), 120 μg/mL streptomycin (Gibco), 55 μM β-
mercaptoethanol (Gibco), and 0.6 mM sodium pyruvate
(Sigma-Aldrich Canada Co., Oakville, ON). D2F2/E2
media contained 800 μg/mL geneticin (Gibco). The
human tumor cell lines SKBR3, HCC1954, and LOX-
IMVI (provided by Dr. Karen Mossman, McMaster
University, Hamilton, ON) were cultured in RPMI
1640 supplemented with 10 % FBS, 2 mM L-glutam-
ine, 10 mM HEPES (Roche Diagnostics, Laval, QC),
100U/mL penicillin, 100 μg/mL streptomycin, and
55 μM β-mercaptoethanol. All cell lines were grown
at 5 % CO2, 95 % air, and 37 °C.
Generation of CAR retroviruses
A murine anti-HER2 scFv CAR (murine scFv28z) was
synthesized at Genscript using the FRP5 scFv sequence
(kindly provided by Dr. Phillip K Darcy (University of
Melbourne, Parkville, Victoria, Australia) [27]; the scFv
[20], was linked to a marker epitope from human c-myc,
the membrane proximal hinge region of murine CD8,
the transmembrane and cytoplasmic regions of murine
CD28, and the cytoplasmic region of murine CD3ζ
(Table 1). The murine scFv28z was cloned into the retro-
viral vector pRV2011 oFL (used for the generation of
CAR –‘ve transduced murine T cells) [28] (kindly pro-
vided by Dr. Brian Rabinovich, MD Anderson, Houston,
TX, USA) which also encodes that Thy1.1 marker gene.
To generate DARPin28z, the FRP5 sequence in murine
scFv28z was replaced with the sequence for the G3 anti-
HER2 DARPin [19] [RCSB Protein Data Bank: 2jab].
The G3 DARPin sequence was synthesized at Genscript
(Piscataway, NJ, USA). Retroviral supernatants were gen-
erated by transient transfection of a packaging cell line
with pRV2011 CAR vectors. CAR retroviral vectors
(10 μg) and the packaging plasmid pCL-Eco (10 μg)
were co-transfected into PLAT-E cells using Lipofecta-
mine 2000 (Invitrogen; Life Technologies). Retrovirus
containing supernatants were collected 48 h later and
concentrated 40-fold using an Amicon Ultra 100 K cen-
trifugal filter (Millipore (Canada) Ltd., Etobicoke, ON);
this process was repeated at 72 h.
Generation of CAR lentiviruses
Human variants of scFv28z and DARPin28z were con-
structed in which the membrane proximal CD8 hinge re-
gion, the transmembrane and cytoplasmic regions of
CD28, and the cytoplasmic region of CD3ζ of the murine
CARs were replaced with the corresponding regions of
their human counterparts (Table 1) (again, the cDNA se-
quence was synthesized at Genscript). Human scFv28z
and DARPin28z CAR sequences were cloned into the len-
tiviral vector pCCL ΔNGFR (used for the generation of
CAR –‘ve transduced human T cells) [29] (kindly provided
by Dr. Megan Levings, University of British Columbia,
Vancouver, BC). CARs were cloned downstream of the
human EF1α promoter leaving ΔNGFR intact downstream
of the minimal cytomegalovirus promoter in a bicistronic
vector, pCCL. Third generation lentiviruses were made for
(See figure on previous page.)
Fig. 2 DARPin28z induces murine CAR-T cell cytokine production upon HER2 stimulation. a 106 scFv28z, DARPin28z, or CAR –’ve transduced
murine T cells were stimulated with HER2 (HER2Fc fusion protein) or an unrelated target (KDRFc fusion protein) for four hours at 37 °C in a 96-well
plate. Production of IFN-γ and TNF-α was measured by intracellular cytokine staining (ICS) and subsequent flow cytometry. Data from CD8+ Thy1.1+ T
cells is presented as mean of n = 3 experiments (CAR –’ve) and n = 5 experiments (scFv28z and DARPin28z) ± SD. Bracketed numbers are quantitative
of the representative plots shown. b Visual comparison of cytokine production data from a. c Cytokine expression data expressed relative to
CAR-positivity of transduced cells where CAR+ transformant = % CAR+/% Thy1.1+. Error bars = SD. * = p < 0.05 ** = p < 0.005 *** = p < 0.001
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each CAR construct; 8 × 106 HEK 293 T cells in 15 cm
tissue culture treated dishes (NUNC) (cultured in
DMEM supplemented with 10 mM HEPES, 2 mM L-
glutamine, 10 % FBS, and 0.1 mg/mL normocin (Invivogen,
San Diego, CA)) were transfected with plasmids pRSV-Rev
(6.25 μg), pMDLg-pRRE (12.5 μg), pMD2.G (9 μg), and
CAR-encoding pCCL (30 μg) (kindly provided by Dr.
Megan Levings, University of British Columbia, Vancouver,
BC) using Lipofectamine 2000. After overnight incubation,
media was replaced and supplemented with 1 mM sodium
butyrate (Sigma-Aldrich). 30 h later, supernatants were
harvested, filtered (0.45 μm), and concentrated (4 °C, 1 hr
40 min, 1.3 × 105rcf). Viral stocks were resuspended in
PBS and stored at −80 °C. Thawed virus aliquots were ti-
trated by serial dilution and transduction of HEK 293 T
cells to determine transduction units per milliliter.
Transduction of murine T cells
Female BALB/c and C57BL/6 mice were purchased from
Charles River Breeding Laboratory (Wilmington, MA). All
of our investigations have been approved by the McMaster
Animal Research Ethics Board. To generate murine T
lymphoctes for retroviral transduction, 3 × 106 freshly iso-
lated splenocytes were cultured in 1 mL T cell media
(RPMI supplemented with 10 % FBS, 2 mM L-glutamine,
10 mM HEPES, 0.5 mM sodium pyruvate, 0.1 mM non-
essential amino acids, 55 μM β-mercaptoethanol, and
0.1 mg/mL normocin or 100U/mL penicillin + 100 μg/mL
streptomycin) supplemented with 0.3 μg/mL α-CD3e
(clone 145-2C11, Cat No. 553057, BD Pharmingen, San
Diego, CA) and 400U/mL rhIL-2 (Cat No. 200–02,
Peprotech, Rocky Hill, NJ). Twenty-four hours after acti-
vation, 600 μL of media were removed from Tcell cultures
and 100 μL of the concentrated retroviral supernatant was
added, along with 2 μg/mL Lipofectamine 2000 and
1.6 μg/mL Polybrene (Sigma-Aldrich). Cultures were spun
at 2000 rpm, 32 °C for 90 min, allowed to rest for 1–4 h,
and were supplemented with 0.5 mL T cell media + 400U/
mL rhIL-2. This process was repeated at 48 h after activa-
tion with the 72 h retroviral concentrates. Seventy-two
hours after activation, retrovirally transduced T cell cul-
tures were expanded into 30 mL of DC media + 400U/mL
rhIL-2. Six to eight days after activation, resultant CAR-T
cells were enumerated for use in vitro.
Transduction of human T cells
Peripheral blood mononuclear cells from healthy donors
were obtained using Ficoll-Paque-Plus (GE Healthcare,
Baie d’Urfe, QC) separation. This research was approved
by the McMaster Health Sciences Research Ethics Board
that operates in compliance with the ICH Good Clinical
Practice Guidelines, the Tri-Council Policy Statement:
Ethical Conduct for Research Involving Humans, Division
5 Health Canada Food and Drug Regulations, and the
Helsinki Declaration. All donors in this study provided in-
formed written consent. 1 × 105 cells were activated with
anti-CD3/CD28 beads at a 1:1 ratio (Dynabeads, Cat No.
11131D, Life Technologies) in a 96-well round bottom
plate (cultured in T cell media) with 100U/mL rhIL-2 and
10 ng/mL rhIL-7. Twenty-four hours after activation, T
cells were transduced with lentivirus at an MOI of 1:1.
CAR-T cell cultures were expanded into fresh media (T
cell media supplemented with 100U/mL rhIL-2 and
10 ng/mL rhIL-7) as required for a period of 10–15 days
prior to enumeration and use in vitro.
Flow cytometry
Detection of CAR constructs on the surfaces of murine or
human T lymphocytes was determined by indirect im-
munofluorescence with HER2Fc chimeric protein (Cat No.
1129-ER-050, R&D Systems, Minneapolis, MN) followed
by a phycoerythrin (PE)-conjugated goat anti-human IgG
(Cat No. 109-115-098, Jackson ImmunoResearch, West
Grove, PA) or anti-myc-tag (clone 9B11, Cell Signaling
Technology, Danvers, MA) followed by a PE-conjugated
goat anti-mouse IgG (Cat No. 115-116-146, Jackson
ImmunoResearch). Cell surface phenotyping of mur-
ine CAR-T cells was determined by direct staining
with AlexaFluor(AF)700-conjugated anti-CD8a (clone
53–6.7, eBioscience Inc., San Diego, CA), PerCP-
Cy5.5-conjugated anti-CD8a (clone 53–6.7, BD Phar-
mingen), PE-conjugated anti-CD8b (clone H35-17.2,
BD Pharmingen), PE-conjugated anti-CD90.1 (Thy1.1,
clone OX-7, BD Pharmingen), and/or fluorescein iso-
thiocyanate (FITC)-conjugated anti-CD90.1 (clone
HIS51, eBioscience Inc.). Cell surface phenotyping of
human CAR-T cells was determined by indirect stain-
ing with HER2Fc chimeric protein (as for murine T
cells) and direct staining with PE-CF594-conjugated
(See figure on previous page.)
Fig. 3 DARPin28z induces human CAR-T cell cytokine production upon HER2 stimulation. 106 scFv28z, DARPin28z, or CAR –’ve transduced human
T cells were stimulated with HER2 (HER2Fc fusion protein) or an unrelated target (KDRFc fusion protein) for four hours at 37 °C in a 96-well plate.
a Production of IFN-γ and TNF-α was measured by ICS and subsequent flow cytometry. Data from CD8+ NGFR+ T cells is presented as mean ± SD.
Bracketed numbers are quantitative of the representative plots shown. b Production of IL-2 by CD8+ NGFR+ T cells as measured by ICS. c Production
of CD107a by CD8+ NGFR+ T cells as measured by ICS. d Pie graphs capturing the distribution of single and multi-functional CAR-T cells as produced
with SPICE software. Pie arcs indicate functional populations represented by pie wedges. Error bars = SD. * = p < 0.05 ** = p < 0.005 *** = p < 0.001. All
data from n = 3 experiments repeated with T cells from two donors


















































































































































































































Fig. 4 DARPin28z murine and human CAR-T cells are capable of killing HER2+ tumor cells. a Expression of HER2 on a panel of five tumor cell lines
was verified by flow cytometry using a primary anti-HER2 antibody followed by a secondary detection antibody (thick lines). Shaded histograms
indicate secondary only controls and numbers indicate mean fluorescence intensity. b-e Transduced murine T cells (effectors) were incubated
together with tumor cells (targets) at various E:T ratios for 6 h in a 96-well plate. Each E:T was tested in triplicate. Error bars = standard error
(SE). f-j Human CAR-T cells were incubated together with tumor cells at various E:T ratios for 6 h. Each E:T was tested in triplicate, data shown
is the mean from n = 3 experiments repeated with T cells from two donors. Error bars = SE. Statistics compare scFv28z vs DARPin28z (* = p < 0.05
** = p < 0.005 *** = p < 0.001)
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anti-CD271 (NGFR, clone C40-1457, BD Biosciences), and
AF700-conjugated anti-CD8a (clone OKT8, eBioscience
Inc.). All flow cytometry was conducted on a BD FACS-
Canto or BD LSRII cytometer (BD Bioscience) and ana-
lyzed using FlowJo vX.0.7 software (FlowJo, LLC, Ashland,
OR, USA).
Functional analysis of CAR-T cells following stimulation
with recombinant protein
106 murine or human CAR-T cells were stimulated in
round bottom tissue culture treated 96-well plates coated
with 200 ng HER2Fc chimeric protein (Cat No. 1129-ER-
050, R&D Systems) or 200 ng KDRFc chimeric protein
(Cat No. 443-KD, R&D Systems) for 4 h at 37 °C. Protein
transport was inhibited according to the BD Golgi Plug
protocol (Cat No. 555029 BD Biosciences, San Diego,
CA). Production of activation cytokines was determined
by flow cytometry. Cells were stained for surface pheno-
type markers as above. To permit intracellular cytokine
staining (ICS), CAR-T cells were fixed and perme-
abilized according to BD Cytofix/Cytoperm Fixation/
Permeabilization Kit protocol (Cat No. 554714, BD Bio-
sciences). ICS of murine CAR-T cells was conducted by
direct staining with allophycocyanin (APC)-conjugated
anti-IFN-γ (clone XMG1.2, BD Pharmingen) and PE-
cyanine(Cy)7-conjugated anti-TNF (clone MP6-XT22,
BD Pharmingen). ICS of human CAR-T cells was con-
ducted by direct staining with APC-conjugated anti-IFN-γ
(clone B27, BD Pharmingen), FITC-conjugated anti-
TNF (clone MAb11, BD Pharmingen), PE-conjugated
anti-IL-2 (clone MQ1-17H12, BD Biosciences), and FITC-
conjugated anti-CD107a (clone H4A3, BD Pharmingen).
Analysis and presentation of distributions was performed
using SPICE version 5.1, downloaded from [30]. Compari-
son of distributions was performed using a Student’s T test
and a partial permutation test as described [31], with a
threshold of 0.09.
In vitro cytotoxicity assay
Adherent tumor cell lines were plated at 1.25 × 104 cells/
well (D2F2, D2F2/E2, HCC1954, or LOX-IMVI) or
1.25 × 104 (human CAR-T cell cytotoxicity assay) or
2.5 × 104 cells/well (murine CAR-T cell cytotoxicity
assay) (SKBR3) overnight in 96-well flat bottom tissue
culture treated plates. Transformed murine or human T
cell cultures were added to wells of tumor cells at vari-
ous E:T ratios (from 0.1:1 to 6:1) and co-incubated to-
gether at 37 °C for 6 h. Murine T cells were added based
on effectors defined as cells from day 6 to 8 transduced
murine T cell cultures. Human T cells were added based
on effectors defined as CAR-positive cells from day 15
transduced human T cell cultures. Wells were washed
3× with warmed PBS to remove any non-adherent cells.
100 μL of a 10 % solution of AlamarBlue cell viability re-
agent (Life Technologies) in T cell media was added and
wells were incubated at 37 °C overnight. Colour change,
indicative of live cells, was measured by fluorescence
(excitation 530 nm, emission 595 nm) on a Safire plate
reader (Tecan, Maennendorf, Switzerland). Tumor cell
viability was calculated as the loss of fluorescence in ex-
perimental wells compared to untreated target cells.
Each condition was tested in triplicate.
Statistical analysis
Student’s t tests, two-tailed, type two, were used to com-
pare data between two groups. Results were prepared
using Microsoft Excel 2010. Significant differences were
defined as: * = p < 0.05, ** = p < 0.01, *** = p < 0.001; NS =
not significant.
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CD8 hinge VISNSVMYFS SVKGTGLDFA
CD28 transmembrane and cytoplasmic ALVVVAGVLF PARDFAAYRP
CD3ζ cytoplasmic LRAKFSRSAE ALHMQTLAPR
Human CAR sequences:
Domain N-terminus C-terminus
CD8 hinge SALSNSIMYF GGAVHTRGLD
CD28 transmembrane and cytoplasmic FWVLVVVGGV PPRDFAAYRS
CD3ζ cytoplasmic RVKFSRSADA ALHMQALPPR
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